Loading...
Loading...
In a recently published report on Endo Pharmaceuticals Holdings Inc.
ENDP , Citigroup has reviewed core product and pricing trends for company's Lidoderm, Opana and Fortesta.
Citigroup sees the company's Lidoderm to have a "~$1,030M Annual Run Rate Implied by 4-Week Average TRx's vs. Our 2011E Sales of ~$806M (+3%). 4Q11 QTD TRx growth is +2% vs. +1%/+1%/+5%/+1% in 3Q11/2Q11/1Q11/4Q10." On Opana, Citigroup sees "~$380M Annual Run Rate Implied by 4-Week Average TRx's vs. Our 2011E Sales of ~$384M (+29%). Branded long-acting opioid TRx market is up +0% in 4Q11 QTD. Total Opana NRx share is 6.2% (-6bps)," Finally, according to Citi, "Fortesta Has 2.1% NRx Share of the Testosterone Replacement Mkt. We project ‘11E Fortesta sales of ~$32M; with NRx/TRx's for the week at 1,051(+9%)/1,784 (+6%)."
On Friday, ENDP closed its trading at $32.71 per share.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in